# Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

> **NCT01289678** · PHASE2 · TERMINATED · sponsor: **Leo W. Jenkins Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT01289678
- **Lead sponsor:** Leo W. Jenkins Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2016-08-31
- **Final completion:** 2016-08-31
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Unable to meet accrual goals
- **Last updated:** 2019-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01289678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01289678, "Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01289678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*